Information and observations on value and health
TEAM OVERVIEWS
ALL NEWS TEAM OVERVIEWS EVENTS THOUGHT LEADERSHIP
About Carlos Bonilla
So far Carlos Bonilla has created 261 blog entries.
Precision Value & Health Acquires Global Omnichannel Engagement Leader, Across Health
Carlos Bonilla2021-03-24T03:33:43+00:00News|
EU-based team brings a unique omnichannel optimization platform and digital transformation capabilities to leading life-sciences companies
BETHESDA, MD—March 24, 2021—Precision Value & Health, the industry leader for commercialization services for innovative life science companies, today announced that it has acquired Across Health. Across Health is a leading global omnichannel engagement consultancy focused on providing clients an analytical and evidence-based framework for commercial strategy, execution, and resource optimization. The company's solutions are based around its proprietary, market-leading Navigator365 product suite, which more than 40 pharmaceutical companies rely on for omnichannel planning and resource allocation. The Across Health team is already working hand-in-hand with Precision's medical communications, creative, and data sciences teams to offer analytically driven launch and commercialization programs across the product life cycle.
Precision Medicine Group Significantly Expands Cell and Gene Therapy Expertise with Acquisition of Project Farma
LEADING BIO-ENGINEERING AND MANUFACTURING SERVICES FIRM CATALYZES THE LAUNCH OF PRECISION'S CELL AND GENE THERAPY OFFERING—'PRECISION ADVANCE'—ADDRESSING THE UNIQUE CHALLENGES OF CELL & GENE THERAPY INNOVATORS, FROM DEVELOPMENT THROUGH COMMERCIALIZATION
BETHESDA, MD—January 14, 2021—Precision Medicine Group ("PMG") announced today it has acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies. Project Farma provides Precision a market-leading expertise in the manufacturing of life-changing medicines, with a unique focus in the rapidly growing area of cell and gene therapy. The acquisition adds Project Farma's unique expertise to Precision's suite of end-to-end cell and gene therapy capabilities to support development and commercialization.
Precision Value & Health Shifts the Trajectory with Convergence of Brands under One Umbrella
REBRANDING LAUNCH EMPHASIZES COMPANY'S INVESTMENT AND PRIORITY IN UNIFYING EXPERTISE AND ACCELERATING CULTURE OF COLLABORATION
New York, NY – April 7th, 2020 – Precision Value & Health, part of Precision Medicine Group, today announced a comprehensive rebranding that includes new names, new logos and updated positioning to accurately reflect its expanded offerings in 2020. To communicate this new positioning and re-aligned capabilities, the company has also rolled out new websites for Precision Value & Health as well as its sub-brands.
Pharma Manufacturers Could See Better Adherence, Outcomes With Focus on SDOH
How much of a roll can pharmaceutical manufacturers play in the social determinants of health? Industry experts, Maureen Hennessey, PhD, and Dominic Galante, MD, discuss how much they can stand to gain in medication adherence and outcomes from partnering with other industry stakeholders and programs around the issue.
Read the full article below.
Why the dance between manufacturers and PBMs continues
There's a simple reason why co-pay accumulators captured the industry's attention when they rolled out in 2017: Healthcare is too damn expensive and co-pay accelerators, at least in theory, offered a financial workaround.
New Issue of ALL ACCESS Available Now: The Key Takeaways of 2019
Carlos Bonilla2020-02-18T15:38:11+00:00Thought Leadership|
What are the biggest key takeaways from 2019? In the latest All Access newsletter by Precision for Value we asked our advisors to reflect on the market events for the year by type of payer. Get your complimentary copy here.
How Development of Gene Therapies Impact Decisions on Their Place in Therapy
Gene therapy has sparked significant interest across the health care industry because it offers the tantalizing possibility of a cure. While gene therapy holds great promise, this field of research is still in its nascent stages, and the optimal methods and solutions for unlocking its full clinical potential are still being defined.
Making Life-Saving Medical Treatments More Affordable
Recent years have brought significant innovation in potentially curative therapies for several diseases. By 2025, the FDA anticipates approving 10 to 20 cell and gene therapy products per year, many of which are intended to be one-time curative treatments.
Novel Value Measures and European HTA: Implications for Pharma/Device HEOR
In the latest edition of IPSOR's Value in Health, Ross Maclean takes an in depth look at several novel measures of value beyond QALY and how they may apply to European health technology assessment.
The Evolution of Value Frameworks and What Is Next
Can the tools we use to measure value keep up with the pace at which oncology is advancing? Explore how four different frameworks have evolved over time and the role they play in oncology value assessment.
Healthcare Agency Roundtable
Self-Reported Health Care Resource Utilization in Clinical Trials
Value-Based Care Can Do More
EP11 How to Build a Snowball with Mike Chambers
Looking Forward to 2022, COVID-19 Will Continue to Impact Pharma in Myriad Ways
Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.
CONTACT PRECISION MEDICINE GROUP
© Precision Medicine Group, LLC. All Rights Reserved.
By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.